Publications
Publications
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Indomethacin is used as standard therapy to close a patent ductus arteriosus (PDA) but is associated with reduced blood flow to several organs.
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Indomethacin is used as standard therapy to close a patent ductus arteriosus (PDA) but is associated with reduced blood flow to several organs.
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.
A patent ductus arteriosus (PDA) with significant left to right shunt increases morbidity and mortality in preterm infants.
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Patent ductus arteriosus (PDA) complicates the clinical course of preterm infants and increases the risk of adverse outcomes.
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates.
Chronic lung disease (CLD) remains an important cause of mortality and morbidity in preterm infants and inflammation plays an important role in its pathogenesis.
Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants.
Chronic lung disease (CLD) remains a serious and common problem among very low birth weight (VLBW) infants despite
Volume targeted ventilation and arterial carbon dioxide in extremely preterm infants.
The aim of our study was to quantify arterial carbon dioxide levels (PaCO2) achieved by ventilating extremely preterm neonates in volume guarantee mode targeting tidal volumes of approximately 4 ml/kg.
